natgillin/translations-raw huggingface dataset:
Patients who also have HIV infection: Lactic acidosis and worsening liver function are side effects associated with Highly Active Anti-Retroviral Therapy (HAART), an HIV treatment.
Bolniki, okuženi s HIV: Neželena učinka, povezana z visoko aktivnim protiretrovirusnim zdravljenjem (HAART, vrsta zdravljenja okužbe s HIV), sta laktoacidoza in slabšanje delovanja jeter.
Commonly reported side effects: thirst, dehydration, high blood pressure, migraines, swollen glands, flushing, menstrual problems, decreased sexual drive, vaginal problem, breast pain, pain in testicle, problems with thyroid gland, red gums, dry mouth, red or sore mouth or tongue, tooth ache or tooth disorder, herpes simplex (fever blisters), taste change, upset stomach, dyspepsia (heartburn), constipation, enlargement of liver (liver problems, sometimes severe), loose stools, bedwetting in children, inflammation of the sinuses, bronchitis, eye pain, problem with your tear ducts, conjunctivitis (“pink eye”), agitation, sleepiness, sleepwalking, problem with behaviour, nervousness, stuffy or runny nose, sneezing, rapid breathing, pale or reddened skin, bruising, problem with skin or nails, psoriasis (new or worsened), increased sweating, increased need to pass urine, fine shaking movements, decreased sensitivity to touch, arthritis.
Pogosto poročani neželeni učinki: žeja, dehidracija, zvišan krvni tlak, migrene, otekle bezgavke, zardevanje, težave z menstruacijo, zmanjšana spolna sla, vaginalne težave, bolečine v dojkah, bolečine v modih, težave z žlezo ščitnico, pordele dlesni, suha usta, pordela ali vneta usta ali jezik, zobobol ali zobne bolezni, herpes simpleks (vročinske razjede), sprememba okusa, želodčne težave, dispepsija (zgaga), zaprtje, povečanje jeter (jetrne težave, včasih hude), vodeno blato, močenje postelje pri otrocih, vnetje sinusov, bronhitis, očesne bolečine, težave s solznimi kanalčki, konjunktivitis (“rdeče oko”), vznemirjenost, zaspanost, hoja v spanju, vedenjske težave, živčnost, zamašen nos ali izcedek iz nosu, kihanje, hitro dihanje, bleda ali pordela koža, podplutbe, težave s kožo ali nohti, luskavica (novonastala ali poslabšanje obstoječe), povečano potenje, večja potreba po odvajanju urina, drobni tresoči gibi, zmanjšana občutljivost za dotik, artritis.
IntronA is available in twelve different pack sizes:
Zdravilo IntronA je na voljo v dvanajstih različnih pakiranjih: 1 viala,
- The other ingredients are disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate, edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections.
- Pomožne snovi so brezvodni natrijev hidrogenfosfat, natrijev dihidrogen fosfat monohidrat, dinatrijev edetat, natrijev klorid, meta-krezol, polisorbat 80 in voda za injekcije.
One dose of IntronA is given on each scheduled day.
Vsak načrtovani dan dajte en odmerek zdravila IntronA.
Excipients: disodium phosphate anhydrous, sodium dihydrogen phosphate monohydrate, edetate disodium, sodium chloride, m-cresol, polysorbate 80 and water for injections.
Pomožne snovi: brezvodni natrijev hidrogenfosfat, natrijev dihidrogen fosfat monohidrat, dinatrijev edetat, natrijev klorid, meta-krezol, polisorbat 80 in voda za injekcije.
Clean the rubber stopper on the top of the vial containing the IntronA solution with a cleansing swab.
S čistilnim tamponom očistite gumijasti zamašek na vrhu viale z raztopino zdravila IntronA.
Severe CNS effects, particularly depression, suicidal ideation and attempted suicide have been observed in some patients during IntronA therapy, and even after treatment discontinuation mainly during the 6-month follow-up period.
Psihiatrične motnje in centralni živčni sistem (CŽS) Med terapijo z zdravilom IntronA in celo po ukinitvi zdravljenja, predvsem v 6-mesečnem obdobju spremljanja, so pri nekaterih bolnikih opažali hude učinke na CŽS, še posebej depresijo, samomorilne misli in poskus samomora.
Chronic Myelogenous Leukaemia: 4-5 million IU/m 2 daily injected subcutaneously (under the skin).
Kronična mieloična levkemija: 4 do 5 milijonov i.e./m 2 na dan s subkutano (podkožno) injekcijo.
Very commonly reported side effects: pain, swelling and redness or skin damage at site of injection, hair loss, dizziness, changes in appetite, stomach or abdominal pains, diarrhoea, nausea (feeling sick), viral infection, depression, emotional lability, insomnia, anxiety, sore throat and painful swallowing, fatigue, chills/rigors, fever, flu-like reaction, feeling of general discomfort, headaches, weight loss, vomiting, irritability, weakness, mood swings, coughing (sometimes severe), shortness of breath, itching, dry skin, rash, sudden and severe muscle pain, joint pain, musculoskeletal pain, changes in laboratory blood values including decreased white blood cell count.
Zelo pogosto poročani neželeni učinki: bolečina, otekanje in pordelost ali poškodbe kože na mestu injiciranja, izpadanje las, omotica, sprememba apetita, želodčne ali trebušne bolečine, driska, slabost (siljenje na bruhanje), virusna okužba, depresija, čustvena nestabilnost, nespečnost, tesnoba, vnetje žrela in bolečine pri požiranju, utrujenost, mrzlica/tresavica, zvišana telesna temperatura, gripi podobna reakcija, občutek splošnega neugodja, glavoboli, hujšanje, bruhanje, razdražljivost, šibkost, nihanje razpoloženja, kašelj (včasih hud), kratka sapa, srbenje, suha koža, izpuščaj, nenadne in hude mišične bolečine, sklepne bolečine, mišičnoskeletne bolečine, spremembe izvidov laboratorijskih krvnih preiskav vključno z zmanjšanim številom belih krvnih celic.
You must use an effective contraceptive during the time you are taking ribavirin and for 4 months after stopping treatment.
V času jemanja ribavirina in še 4 mesece po zaključku zdravljenja morate uporabljati učinkovito kontracepcijo.
18 million IU/3 mL solution for injection or infusion 1 multiple dose vial
18 milijonov i.e./3 ml raztopina za injiciranje ali infundiranje 1 viala z večkratnimi odmerki
Patients were randomized to receive either pegylated interferon alfa-2b (100 or 150 µg /week based on weight) plus ribavirin (800-1,200 mg/day based on weight) or IntronA (3 MIU TIW) plus ribavirin (800-1,200 mg/day based on weight).
Bolnike so naključno razporedili bodisi v skupino, ki je prejemala pegiliran interferon alfa-2b (v odmerkih 100 ali 150 µg/teden, odvisno od telesne mase) z ribavirinom (v odmerku 800-1.200 mg/dan, odvisno od telesne mase), ali pa v skupino, ki je prejemala zdravilo IntronA (3 m.i.e.
As induction therapy, interferon alfa-2b is administered intravenously at a dose of 20 million IU/m daily for five days a week for a four-week period; the calculated interferon alfa-2b dose is added to sodium chloride 9 mg/mL (0.9 %) solution for injection and administered as a 20-minute infusion (see section 6.6).
Izračunani odmerek interferona alfa-2b dodajte natrijevemu kloridu 9 mg/ml (0,9 %) raztopini za injekcije in ga dajte bolniku v 20-minutni infuziji (glejte poglavje 6.6).
Photosensitivity reaction, maculopapular rash, eczema, acne, skin disorder, nail disorder, skin discolouration, pruritus, dry skin, erythema, bruise, sweating increased
alopecija, izpuščaj fotosenzitivne reakcije, makulopapulozni izpuščaj, ekcem, akne, kožne bolezni, bolezni nohtov, obarvanje kože, pruritus, suha koža, eritem, modrice, povečano potenje
IntronA therapy may be initiated if TSH levels can be maintained in the normal range by medication.
Terapijo z zdravilom IntronA lahko začnete, če je koncentracijo TSH mogoče z zdravili ohranjati v normalnem razponu vrednosti.
Pack of 12 vials, 72 injection syringes with attached needle of 1 mL and 144 cleansing swabs Not all pack sizes may be marketed.
12 vial, 72 (1-mililitrskih) injekcijskih brizg s pritrjeno iglo in 144 čistilnih tamponov Na trgu morda ni vseh navedenih pakiranj.
Corresponding dose (million IU) using IntronA 25 million IU/2.5 mL solution for injection or infusion
Ustrezen odmerek (milijoni i.e.) uporabljenega zdravila IntronA 25 milijonov i.e./2,5 ml raztopina za injiciranje ali infundiranje
Results from the clinical trial conducted with pegylated interferon alfa-2b and ribavirin In a multicentre trial children and adolescents 3 to 17 years of age with compensated chronic hepatitis C and detectable HCV-RNA were treated with peginterferon alfa-2b 60 g/m2 plus ribavirin
Izsledki kliničnega preskušanja, opravljenega s pegiliranim interferonom alfa-2b in ribavirinom Otroke in mladostnike, stare od 3 do 17 let, s kompenziranim kroničnim hepatitisom C in merljivimi vrednostmi HCV-RNA so vključili v multicentrično preskušanje in jih zdravili s peginterferonom alfa2b v odmerku 60 g/m2 in ribavirinom v odmerku 15 mg/kg na dan enkrat na teden v obdobju 24 ali 48 tednov, glede na genotip HCV in virusno breme na začetku preskušanja.
Corresponding dose (million IU) using IntronA 18 million IU/3 mL solution for injection or infusion
Ustrezen odmerek (milijoni i.e.) uporabljenega zdravila IntronA 18 milijonov i.e./3 ml raztopina za injiciranje ali infundiranje
In the presence of thyroid dysfunction, IntronA treatment may be continued if TSH levels can be maintained in the normal range by medication.
V primeru motenj delovanja žleze ščitnice lahko terapijo z zdravilom IntronA nadaljujete, če boste z zdravili lahko ohranjali koncentracijo TSH v normalnem razponu vrednosti.
Follicular lymphoma: Adjunctively with chemotherapy, 5 million IU 3 times a week (every other day) injected subcutaneously (under the skin).
Folikularni limfom: dodatno ob kemoterapiji, 5 milijonov i.e. 3-krat na teden (vsak drugi dan) s subkutano (podkožno) injekcijo.
IntronA 5 MIU
IntronA 5 mio i.e.
Treatment should be continued for another 6-month period (i.e., a total of 12 months) in patients who exhibit negative HCV-RNA at month 6, and with viral genotype 1 (as determined in a pre-treatment sample) and high pre-treatment viral load.
Pri bolnikih z negativnim izvidom HCV-RNA po 6 mesecih, virusnim genotipom 1 (določenim v vzorcu, odvzetem pred terapijo) ter veliko virusno obremenitvijo pred začetkom zdravljenja zdravljenje podaljšajte še za 6 mesecev (t.j.
IntronA 18 million IU/3 mL solution for injection or infusion
IntronA 18 milijonov i.e./3 ml raztopina za injiciranje ali infundiranje
If treatment with alpha interferon is judged necessary in these patients, the presence of psychiatric co-morbidities and the potential for other substance use should be carefully assessed and adequately managed before initiating therapy.
Če ocenite, da je pri takšnih bolnikih zdravljenje z interferonom alfa potrebno, morate pri njih skrbno preveriti, ali imajo morda kakšno sočasno psihiatrično motnjo in če obstaja možnost uživanja opojnih substanc.
Check with your doctor if you think you are getting an infection.
Če mislite, da ste se okužili, se posvetujte z zdravnikom.
Co-administration of IntronA with ribavirin increased the efficacy of IntronA by at least two fold for the treatment of chronic hepatitis C in naïve patients.
Sočasna uporaba zdravila IntronA z ribavirinom za zdravljenje kroničnega hepatitisa C pri predhodno nezdravljenih bolnikih je povečala učinkovitost zdravila IntronA za najmanj dvakrat.
IntronA treatment may be initiated if TSH levels can be maintained in the normal range by medication.
Zdravljenje z zdravilom IntronA lahko uvedete, če boste vrednosti TSH lahko z zdravili ohranjali v normalnem razponu.
In addition, dry mouth could have a damaging effect on teeth and mucous membranes of the mouth during long-term treatment with the combination of IntronA and ribavirin.
Poleg tega bi lahko med dolgotrajnim zdravljenjem s kombinacijo zdravila IntronA in ribavirina imela škodljiv vpliv na zobe in ustno sluznico tudi suha usta.
IntronA is administered subcutaneously at a dose of 3 million IU three times a week (every other day) to adult patients, whether administered as monotherapy or in combination with ribavirin.
Pri odraslih bolnikih se zdravilo IntronA uporablja subkutano v odmerku 3 milijone i.e. trikrat na teden (vsak drugi dan) ne glede na to, ali se zdravilo uporablja v monoterapiji ali v kombinirani terapiji z ribavirinom.
Check with your doctor immediately if any of the following side effects occur: - chest pain or persistent and severe cough; irregular or rapid heartbeat; shortness of breath, confusion, difficulty remaining alert, numbness or tingling sensation or pain in hands or feet; seizure (convulsions); trouble sleeping, thinking or concentrating; altered mental state; suicidal thoughts, suicide attempt, changed behaviour or aggressive behaviour (sometimes directed against others), hallucinations; severe stomach pain; black or tar like stools; blood in stool or urine, severe nosebleed; waxy pallor, high sugar level in blood, fever or chills beginning after a few weeks of treatment, lower back or side pain, difficult urination, problems with your eyes or your eyesight or hearing, loss of hearing, severe or painful reddening or sores on your skin or mucous membrane.
• bolečina v prsih ali trdovraten in hud kašelj; neredno ali hitro bitje srca; kratka sapa, zmedenost, težava ostati buden, odrevenelost ali mravljinčenje ali bolečina v dlaneh ali stopalih; epileptični napadi (konvulzije); težave s spanjem, razmišljanjem ali zbranostjo; spremenjeno duševno stanje; samomorilne misli, poskus samomora, spremenjeno obnašanje ali agresivno obnašanje (včasih usmerjeno proti drugim), halucinacije; hude želodčne bolečine; črno ali smolnato blato; kri v blatu ali urinu, huda krvavitev iz nosu; voskasta bledica, visoka raven sladkorja v krvi, zvišana telesna temperatura ali mrzlica, ki nastopi po nekaj tednih zdravljenja, bolečina v spodnjem delu hrbta ali ob strani, težave z uriniranjem, težave z očmi ali vidom ali sluhom, izguba sluha, huda ali boleča pordelost ali ranice na koži ali sluznicah.
3 million IU/0.5 mL
3 milijoni i.e./0,5 ml
Pack of 12 vials
12 vial
One vial contains 18 million IU of interferon alfa-2b in 3 mL of solution.
Ena viala vsebuje 18 milijonov i.e. interferona alfa-2b v 3 ml raztopine.
Very rarely: Not known:
Zelo redki: Neznana pogostnost:
Use IntronA exactly as prescribed by your doctor.
Pri uporabi zdravila IntronA natančno upoštevajte zdravnikova navodila.
The treatment is to be temporarily discontinued during and after surgery.
Med kirurškim posegom in po njem zdravljenje začasno prekinite.
c: Patients with genotype 3 low viral load (< 600,000 IU/mL) were to receive 24 weeks of treatment while those with genotype 3 and high viral load (≥ 600,000 IU/mL) were to receive 48 weeks of treatment.
b: n = število preiskovancev, ki so se odzvali na zdravljenje /število preiskovancev z danim genotipom virusa ter določeno dolžino zdravljenja c: Bolniki z genotipom 3 in majhnim virusnim bremenom (< 600.000 i.e./ml) so prejeli 24-tedensko zdravljenje, tisti z genotipom 3 in velikim virusnim bremenom (≥ 600.000 i.e./ml) so prejeli 48- tedensko zdravljenje.
HOW TO SELF INJECT INTRONA Syringe with an attached needle
KAKO SI LAHKO SAMI INJICIRATE ZDRAVILO INTRONA Brizga s pritrjeno iglo
Weight decrease *These events were only common with IntronA alone.
hujšanje *Ti učinki so bili pogosti samo pri jemanju zdravila IntronA v monoterapiji.
Carcinoid tumour: 5 million IU, 3 times a week (every other day) injected subcutaneously (under the skin).
Karcinoidni tumor: 5 milijonov i.e. 3-krat na teden (vsak drugi dan) s subkutano (podkožno) injekcijo.
§, malaise, irritability Chest pain, asthenia, oedema, injection site pain
§, splošno slabo počutje, razdražljivost, bolečine v prsnem košu, astenija, edem, bolečine na mestu injiciranja
The efficacy and safety of IntronA in combination with ribavirin has been studied in children and adolescents who have not been previously treated for chronic hepatitis C.
Bolniki, ki še niso bili zdravljeni (otroci in mladostniki) Varnost in učinkovitost zdravljenja s kombinacijo zdravila IntronA in ribavirina so preučevali pri otrocih in mladostnikih, ki jih predhodno še niso zdravili zaradi hepatitisa C.
EU/1/99/127/050 12 multiple dose vial, 72 injection syringes with attached needle and needle protection device of 1 mL and 144 cleansing swabs EU/1/99/127/053 12 multiple dose vial, 72 injection syringes with attached needle of 1 mL and 144 cleansing swabs
EU/1/99/127/050 12 vial z večkratnimi odmerki, 72 (1-mililitrskih) injekcijskih brizg s pritrjeno iglo ter pripomočkom za zaščito igle in 144 čistilnih tamponov EU/1/99/127/053 12 vial z večkratnimi odmerki, 72 (1-mililitrskih) injekcijskih brizg s pritrjeno iglo in 144 čistilnih tamponov
IntronA 3 MIU
IntronA 3 mio i.e.
Children 3 years of age and older and adolescents - 3 million IU/m2 3 times a week (every other day) injected subcutaneously (under the skin) in combination with ribavirin (Please also see ribavirin package leaflet).
Otroci, stari 3 leta ali več, in mladostniki - 3 milijoni i.e./m 3-krat na teden (vsak drugi dan) s subkutano (podkožno) injekcijo v kombinaciji z ribavirinom.
Skin and subcutaneous tissue disorders
Bolezni zob in obzobnih tkiv
- IntronA in combination with ribavirin
- Zdravilo IntronA v kombinaciji z ribavirinom
Chronic myelogenous leukaemia
Kronična mieloična levkemija
One vial contains 10 million IU of interferon alfa-2b in 1 mL of solution.
Ena viala vsebuje 10 milijonov i.e. interferona alfa-2b v 1 ml raztopine.
Collect necessary items before you begin: - a vial of IntronA solution for injection; - a 1 mL syringe with an attached needle and a needle protection device (BD SafetyGlide syringe); - a cleansing swab.
Priprava Preden začnete, si pripravite vse potrebne pripomočke: vialo zdravila IntronA raztopina za injiciranje, 1-mililitrsko brizgo s pritrjeno iglo in pripomočkom za zaščito igle (BD SafetyGlide brizga), čistilni tampon.
IntronA 10 MIU
IntronA 10 mio i.e.
Acute hypersensitivity reactions (e.g., urticaria, angioedema, bronchoconstriction, anaphylaxis) to interferon alfa-2b have been observed rarely during IntronA therapy.
Redko so med terapijo z zdravilom IntronA opažali akutne preobčutljivostne reakcije na interferon alfa-2b (npr. urtikarijo, angioedem, bronhokonstrikcijo, anafilaktične reakcije).
Ensure that needle with needle guard is firmly attached to the syringe by pushing while turning the needle guard.
Prepričajte se, da je igla z zaščitnim pokrovčkom trdno pritrjena na brizgo.
Collect necessary items before you begin: - a vial of IntronA solution for injection; - a syringe with an attached needle for subcutaneous injection; - a cleansing swab.
Priprava Preden začnete, si pripravite vse potrebne pripomočke: vialo zdravila IntronA raztopina za injiciranje, brizgo za subkutano injiciranje s pritrjeno iglo, čistilni tampon.
25 million IU/2.5 mL solution for injection or infusion 1 multiple dose vial
25 milijonov i.e./2,5 ml raztopina za injiciranje ali infundiranje 1 viala z večkratnimi odmerki
Therefore, the combination of IntronA with telbivudine is contraindicated.
Ti učinki so lahko tudi resnejši, zato je uporaba kombinacije zdravila IntronA in telbivudina kontraindicirana.
Rotate the needle protection device for bevel orientation or scale readability.
Pripomoček za zaščito igle obrnite v poševen položaj oziroma tako, da lahko vidite merilno skalo.
IntronA 10 million IU/mL solution for injection or infusion
IntronA 10 milijonov i.e./ml raztopina za injiciranje ali infundiranje
Be sure to seek emergency care if you notice that you are becoming depressed or have suicidal thoughts or change in your behaviour.
Če opazite, da postajate depresivni ali imate samomorilne misli oz. se je vaše obnašanje spremenilo, morate poiskati nujno medicinsko pomoč.
IntronA (3 MIU TIW) + ribavirin (800 mg)
trikrat na teden) + ribavirin (800 mg)
IntronA plus ribavirin
Zdravilo IntronA in ribavirin
Cardiomyopathy, that may be reversible upon discontinuation of interferon alpha, has been reported rarely in patients without prior evidence of cardiac disease (see section 4.4).
V redkih primerih so pri bolnikih, ki prej niso imeli nikakršnih znakov srčne bolezni, poročali o kardiomiopatiji, ki je po ukinitvi interferona alfa lahko reverzibilna (glejte poglavje 4.4).
IntronA 25 million IU/2.5 mL solution for injection or infusion
IntronA 25 milijonov i.e./2,5 ml raztopina za injiciranje ali infundiranje
Some people get depressed when taking IntronA alone or in combination treatment with ribavirin, and in some cases people had thoughts about threatening the life of others, suicidal thoughts or aggressive behaviour (sometimes directed against others).
V nekaterih primerih so se pri bolnikih pojavile misli, kako ogroziti življenje drugih, samomorilne misli ali agresivno obnašanje (včasih usmerjeno proti drugim), nekaj bolnikov pa je dejansko naredilo samomor.
Table 5 Sustained virological response in previously untreated children and adolescents IntronA 3 MIU/m2 3 times a week ribavirin 15 mg/kg/day
IntronA 3 mio i.e./m2 3-krat na teden ribavirin 15 mg/kg/dan
Conjunctivitis, vision abnormal, lacrimal gland disorder, eye pain
konjunktivitis, boleče oči, motnje vida, bolezni solzne žleze
Pure red cell aplasia, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura
levkopenija trombocitopenija, limfadenopatija, limfopenija aplastična anemija čista aplazija eritrocitov, idiopatska trombocitopenična purpura, trombotična trombocitopenična purpura
Hairy Cell Leukaemia: 2 million IU/m 2, 3 times a week (every other day) injected subcutaneously (under the skin).
Dlakastocelična levkemija: 2 milijona i.e./m 2, 3-krat na teden (vsak drugi dan) s subkutano (podkožno)
One vial contains 25 million IU of interferon alfa-2b in 2.5 mL of solution.
Ena viala vsebuje 25 milijonov i.e. interferona alfa-2b v 2,5 ml raztopine.
IntronA 5 million IU/0.5 mL solution for injection or infusion
IntronA 5 milijonov i.e./0,5 ml raztopina za injiciranje ali infundiranje
In addition, injection site disorders, pyrexia, anorexia, vomiting, and emotional lability occurred more frequently in children and adolescents compared to adult patients.
Poleg tega so se pri otrocih in mladostnikih pogosteje kot pri odraslih bolnikih pojavile težave na mestu injiciranja, zvišana telesna temperatura, anoreksija, bruhanje in čustvena labilnost.
Collect necessary items before you begin: - a vial of IntronA solution for injection; - a syringe (for example 2 mL); - a needle for the subcutaneous injection (for example 0.4 x 13 mm [27 gauge 0.5 inch]); - a cleansing swab.
Priprava Preden začnete, si pripravite vse potrebne pripomočke: vialo zdravila IntronA raztopina za injiciranje, brizgo (npr. 2-mililitrsko), iglo za subkutano injiciranje (npr. 0,4  13 mm), čistilni tampon.
For example, in a trial of high-dose adjuvant IntronA treatment in patients with melanoma, incidences of fatigue, pyrexia, myalgia, neutropaenia/anaemia, anorexia, nausea and vomiting, diarrhoea, chills, flulike symptoms, depression, alopecia, altered taste, and dizziness were greater than in the hepatitis C trials.
Na primer, v raziskavi adjuvantne terapije z velikimi odmerki zdravila IntronA pri bolnikih z melanomom so bile pojavnosti utrujenosti, zvišane telesne temperature, mialgije, nevtropenije oz. anemije, anoreksije, navzeje in bruhanja, driske, mrzlice, gripi podobni simptomov, depresije, alopecije, sprememb okusa in omotice večje kot v raziskavah hepatitisa C. Tudi njihova jakost se je pri terapiji z velikimi odmerki povečala (stopnja 3 po WHO pri 66 % bolnikov in stopnja 4 po WHO pri 14 % bolnikov) v primerjavi z blago do zmerno jakostjo, ki se običajno pojavlja pri manjših odmerkih.
Each vial contains 5 million IU in 0.5 mL of solution.
Ena viala vsebuje 5 milijonov i.e. v 0,5 ml raztopine.
SVR after treatment of chronic HCV with non-pegylated interferon alfa-2b (with or without ribavirin) results in long-term clearance of the virus providing resolution of the hepatic infection and clinical 'cure' from chronic HCV.
Trajni virološki odziv po zdravljenju kronične okužbe z virusom hepatitisa C z nepegiliranim interferonom alfa-2b (z ali brez ribavirina) vodi do dolgotrajnega očistka virusa ter tako odpravi jetrno okužbo in omogoči klinično »ozdravitev« kronične okužbe z virusom hepatitisa C. To pa ne pomeni, da ne bo prišlo do jetrnih dogodkov pri bolnikih s cirozo (vključno s hepatokarcinomom).